ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Fasenra Shows Consistent Safety, Efficacy in Long-Term in Severe Eosinophilic Asthma Trial
September 20, 2018AstraZeneca announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of
Pharma Sources Insight January 2025
